![]() |
產(chǎn)地 | 進(jìn)口、國(guó)產(chǎn) |
品牌 | 上海莼試 |
保存條件 | Store at -20 °C |
貨號(hào) | CS12242 |
應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 |
CAS編號(hào) | |
抗體名 | Anti-SLC27A4/FATP4 |
克隆性 | 是 |
靶點(diǎn) | 詳見(jiàn)說(shuō)明書(shū) |
適應(yīng)物種 | 詳見(jiàn)說(shuō)明書(shū) |
形態(tài) | 詳見(jiàn)說(shuō)明書(shū) |
宿主 | 詳見(jiàn)說(shuō)明書(shū) |
亞型 | IgG |
標(biāo)識(shí)物 | 詳見(jiàn)說(shuō)明書(shū) |
濃度 | 1mg/1ml% |
免疫原 | KLH conjugated synthetic peptide derived from human SLC27A4 |
抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn):
1. 長(zhǎng)鏈脂肪酸轉(zhuǎn)運(yùn)蛋白4抗體規(guī)格 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析;
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來(lái)篩選最適條件;
3.用NHSB量過(guò)量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活;
4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等;
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性;
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價(jià)結(jié)合;
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競(jìng)爭(zhēng)作用;
8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。
產(chǎn)品訂購(gòu)信息:
英文名稱 Anti-SLC27A4/FATP4
中文名稱 長(zhǎng)鏈脂肪酸轉(zhuǎn)運(yùn)蛋白4抗體規(guī)格
別 名 ACSVL 4; ACSVL-4; ACSVL4; EC 6.2.1; FATP 4; FATP4; Fatty acid transport protein 4; Fatty acid transport protein4; IPS; Long chain fatty acid transport protein 4; Long chain fatty acid transport protein4; OTTHUMP00000022264; S27A4; SLC27 A4; SLC27A 4; Solute carrier family 27 (fatty acid transporter) member 4; Solute carrier family 27 member 4; Solute carrier family 27 member4; S27A4_HUMAN.
濃 度 1mg/1ml
規(guī) 格 0.1ml/100μg 0.2ml/200μg
抗體來(lái)源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Chicken, Pig, Cow, Horse
產(chǎn)品類型 一抗
研究領(lǐng)域 心 神經(jīng)生物學(xué) 信號(hào)轉(zhuǎn)導(dǎo)
蛋白分子量 predicted molecular weight: 72kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human SLC27A4
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
長(zhǎng)鏈脂肪酸轉(zhuǎn)運(yùn)蛋白4抗體規(guī)格 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
(石蠟切片需做抗原修復(fù))
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 SLC27A4 / FATP4 plays a role in the transport of long chain fatty acids across the plasma membrane. It has acyl-coA ligase activity for long chain and very long chain fatty acids. Deletion of the SLC27A4 gene results in embryonic lethality, which is attributed to the need for fat absorption across the visceral endoderm early in embryonic development. Expression of FAT4P in the intestinal lining is thought to be altered in response to dietary fat.
Function : nvolved in translocation of long-chain fatty acids (LFCA) across the plasma membrane. Appears to be the principal fatty acid transporter in small intestinal enterocytes. Plays a role in the formation of the epidermal barrier. Required for fat absorption in early embryogenesis. Has acyl-CoA ligase activity for long-chain and very-long-chain fatty acids
Subcellular Location : Membrane; Multi-pass membrane protein
Tissue Specificity : Expressed at highest levels in brain, testis, colon and kidney. Expressed at medium levels in heart and liver, small intestine and stomach. Expressed at low levels in peripheral leukocytes, bone marrow, skeletal muscle and aorta. Expressed in adipose tissue.
DISEASE : Defects in SLC27A4 are the cause of ichthyosis prematurity syndrome (IPS) [MIM:608649]. A keratinization disorder characterized by complications in the second trimester of pregnancy resulting from polyhydramnion, with premature birth of a child with thick caseous desquamating epidermis, respiratory complications and transient eosinophilia. After recovery during the first months of life, the symptoms are relatively benign and the patients suffer from a lifelong non-scaly ichthyosis with atopic manifestations.
Similarity : Belongs to the ATP-dependent AMP-binding enzyme family.
抗體的鑒定:
1)長(zhǎng)鏈脂肪酸轉(zhuǎn)運(yùn)蛋白4抗體規(guī)格 抗體的效價(jià)鑒定:不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來(lái)鑒定。
2)抗體的特異性鑒定:抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力。抗體的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來(lái)表示。交叉反應(yīng)率可用競(jìng)爭(zhēng)抑制試驗(yàn)測(cè)定。以不同濃度抗原和近似抗原分別做競(jìng)爭(zhēng)抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無(wú)窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3)抗體親和力:是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫(kù)侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol??贵w親和力的測(cè)定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。
TNF受體關(guān)聯(lián)因子7 多克隆抗體 TRAF7 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
驅(qū)動(dòng)蛋白結(jié)合蛋白1 多克隆抗體 TRAK1 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
髓細(xì)胞觸發(fā)受體2 多克隆抗體 TREM2 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
黑素轉(zhuǎn)鐵蛋白 多克隆抗體 TRFM Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
含三聯(lián)基元蛋白23 多克隆抗體 TRI23 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
抗激素/升壓素/加壓素/加壓素抗體 整合素αE抗體Integrin αE
ATP結(jié)合盒蛋白家族GCN20F家族1抗體 整合素α7抗體
激素受體相關(guān)蛋白16抗體 整合素α6抗體
β淀粉樣肽1-40 C端/Aβ1-40 C端抗體 整合素α5抗體Integrin α5
含錨蛋白重復(fù)序列-細(xì)胞因子信號(hào)抑制物盒蛋白家族13抗體 整合素α4抗體
血小板衍生生長(zhǎng)因子受體β (phospho Tyr1021) 多克隆抗體 PDGFR-β (phospho Tyr1021) Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
真核翻譯啟動(dòng)因子 2-alpha激酶(phospho Thr981) 多克隆抗體 PERK (phospho Thr981) Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
fms樣酪氨酸激酶1(phospho Tyr1048) 多克隆抗體 Flt-1 (phospho Tyr1048) Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
突觸核蛋白α (phospho Tyr125) 多克隆抗體 Synuclein-α (phospho Tyr125) Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
ERK 1/2 (phospho Thr202/Y204) 多克隆抗體 ERK 1/2 (phospho Thr202/Y204) Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
石榴Punica granatum L. Punicalin 石榴皮鞣素 65995-64-4 C34H22O22 ≥98%
花椒毒速XcnthotoxinHPLC≥98%,20mg/支
豆甾醇;豆固醇 Stigmasterol 201-482-7 20mg HPLC≥98% 用于含量測(cè)定
中藥對(duì)照藥材胡椒(黑胡椒)121440-200401TLC法鑒別
cedrol,cedar camphor,cypress camphor雪松醇純度:≥97%
長(zhǎng)鏈脂肪酸轉(zhuǎn)運(yùn)蛋白4抗體規(guī)格輕臭檳榔堿 Arecoline xy7nobromide 分 子 量:236.1100 CAS編號(hào):300-08-3 分子式:C8H14BrNO2 別 名:檳榔堿輕臭鹽;輕臭檳榔堿;輕臭丙胺 基本用途:含量測(cè)定。
云南含笑Michelia yunnanensis Reynosin 喘諾木烯內(nèi)酯 28254-53-7 C15H20O3 模擬天然水銅溶液成分分析標(biāo)準(zhǔn)物質(zhì)-銅080 97
中藥對(duì)照藥材魚(yú)腥草121046-200403TLC法鑒別
Eleheroside B刺五加苷B純度:95%
余甘子Phyllanthus emblica Lup-20(29)-ene-3α,23-diol 20(29)-扇豆烯-3,23-二醇 32451-85-7 C30H50O2 ≥98.5%